Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Forma Therapeutics stock | $18.09

Learn how to easily invest in Forma Therapeutics stock.

Forma Therapeutics Holdings Inc is a biotechnology business based in the US. Forma Therapeutics shares (FMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Forma Therapeutics employs 139 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Forma Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FMTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Forma Therapeutics stock price (NASDAQ: FMTX)

Use our graph to track the performance of FMTX stocks over time.

Forma Therapeutics shares at a glance

Information last updated 2021-10-10.
Latest market close$18.09
52-week range$18.57 - $52.75
50-day moving average $23.29
200-day moving average $25.20
Wall St. target price$56.29
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.05

Buy Forma Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Forma Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Forma Therapeutics price performance over time

Historical closes compared with the close of $18.09 from 2021-10-15

1 week (2021-10-08) -3.42%
1 month (2021-09-17) -23.70%
3 months (2021-07-16) -23.18%
6 months (2021-04-16) -29.47%
1 year (2020-10-16) -63.79%
2 years (2019-10-13) N/A
3 years (2018-10-13) N/A
5 years (2016-10-13) N/A

Forma Therapeutics financials

Revenue TTM $7.4 million
Gross profit TTM $-93,367,000
Return on assets TTM -16.81%
Return on equity TTM -26.67%
Profit margin 0%
Book value $12.24
Market capitalisation $934.5 million

TTM: trailing 12 months

Shorting Forma Therapeutics shares

There are currently 2.8 million Forma Therapeutics shares held short by investors – that's known as Forma Therapeutics's "short interest". This figure is 8.5% down from 3.1 million last month.

There are a few different ways that this level of interest in shorting Forma Therapeutics shares can be evaluated.

Forma Therapeutics's "short interest ratio" (SIR)

Forma Therapeutics's "short interest ratio" (SIR) is the quantity of Forma Therapeutics shares currently shorted divided by the average quantity of Forma Therapeutics shares traded daily (recently around 247207.10526316). Forma Therapeutics's SIR currently stands at 11.4. In other words for every 100,000 Forma Therapeutics shares traded daily on the market, roughly 11400 shares are currently held short.

However Forma Therapeutics's short interest can also be evaluated against the total number of Forma Therapeutics shares, or, against the total number of tradable Forma Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Forma Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Forma Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.121% of the tradable shares (for every 100,000 tradable Forma Therapeutics shares, roughly 121 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Forma Therapeutics.

Find out more about how you can short Forma Therapeutics stock.

Forma Therapeutics share dividends

We're not expecting Forma Therapeutics to pay a dividend over the next 12 months.

Forma Therapeutics overview

Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions

What percentage of Forma Therapeutics is owned by insiders or institutions?
Currently 7.734% of Forma Therapeutics shares are held by insiders and 91.671% by institutions.
How many people work for Forma Therapeutics?
Latest data suggests 139 work at Forma Therapeutics.
When does the fiscal year end for Forma Therapeutics?
Forma Therapeutics's fiscal year ends in December.
Where is Forma Therapeutics based?
Forma Therapeutics's address is: 500 Arsenal Street, Watertown, MA, United States, 02472
What is Forma Therapeutics's ISIN number?
Forma Therapeutics's international securities identification number is: US34633R1041

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site